New Japan Partner For Solasia’s Key Oncology Project
This article was originally published in PharmAsia News
Executive Summary
The Japanese venture Solasia has signed a product licensing and investment agreement with major firm Meiji Seika that will support the planned commercialization of its major oncology prospect.
You may also be interested in...
Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition
F-star's novel bispecific technology attracts Sino Biopharma-affiliated acquisition, Shionogi agreement with GARDP brings antibiotic cefiderocol to 135 countries, deal with WinHealth covering Greater China expands Quoin’s licensing of Netherton syndrome candidate to 60 nations, Kyorin and CellGenTech team up in Fabry disease.
Shionogi Hit By Surprise Japan Road Bump For Oral COVID Drug
After months of speculation and anticipation, Shionogi’s once-daily oral antiviral for the treatment of COVID-19 has stumbled after receiving an unexpected preliminary decision on its emergency approval from an advisory committee in Japan.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: key takeaways from BIO; a new alopecia option in the US; how one small specialist company entered Japan; and the evolving BTK inhibitor landscape in multiple sclerosis.